These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35738971)

  • 1. Opsonophagocytic activity against Streptococcus pneumoniae in Indigenous and non-Indigenous patients with severe chronic kidney disease immunized with 13-valent pneumococcal conjugate vaccine.
    Ulanova M; Huska B; Dubois S; McCready W
    Vaccine; 2022 Jul; 40(32):4594-4602. PubMed ID: 35738971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naïve and previously immunized adult patients with severe chronic kidney disease.
    Ulanova M; Huska B; Desbiens A; Gaultier GN; Domonkos V; McCready WG
    Vaccine; 2021 Jan; 39(4):699-710. PubMed ID: 33358702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of pneumococcal immunization on total and antigen-specific B cells in patients with severe chronic kidney disease.
    Gaultier GN; McCready W; Ulanova M
    BMC Immunol; 2019 Nov; 20(1):41. PubMed ID: 31718534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis.
    Vadlamudi NK; Parhar K; Altre Malana KL; Kang A; Marra F
    Vaccine; 2019 Feb; 37(8):1021-1029. PubMed ID: 30685252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.
    Adigweme I; Futa A; Saidy-Jah E; Edem B; Akpalu E; Dibbasey T; Sethna V; Dhere R; Kampmann B; Bengt C; Sirr J; Hosken N; Goldblatt D; Antony K; Alderson MR; Lamola S; Clarke E
    Lancet Infect Dis; 2023 May; 23(5):609-620. PubMed ID: 36638819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
    Bryant KA; Block SL; Baker SA; Gruber WC; Scott DA;
    Pediatrics; 2010 May; 125(5):866-75. PubMed ID: 20435707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children.
    Ryman J; Sachs JR; Yee KL; Banniettis N; Weaver J; Weiss T
    Expert Rev Vaccines; 2024; 23(1):60-68. PubMed ID: 38073483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Peterson JT; Stacey HL; MacNair JE; Li J; Hartzel JS; Sterling TM; Benner P; Tamms GM; Musey LK
    Hum Vaccin Immunother; 2019; 15(3):540-548. PubMed ID: 30427749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trial.
    Borys D; Rupp R; Smulders R; Chichili GR; Kovanda LL; Santos V; Malinoski F; Siber G; Malley R; Sebastian S
    Vaccine; 2024 Apr; 42(10):2560-2571. PubMed ID: 38360475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age.
    Ermlich SJ; Andrews CP; Folkerth S; Rupp R; Greenberg D; McFetridge RD; Hartzel J; Marchese RD; Stek JE; Abeygunawardana C; Musey LK
    Vaccine; 2018 Oct; 36(45):6875-6882. PubMed ID: 29559167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.
    Sigurdardottir ST; Center KJ; Davidsdottir K; Arason VA; Hjalmarsson B; Elisdottir R; Ingolfsdottir G; Northington R; Scott DA; Jonsdottir I
    Vaccine; 2014 Jan; 32(3):417-24. PubMed ID: 24300594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of pneumococcal immunogenicity elicited by the PCV13 and PCV15 vaccines in adults 18 through 49 years of age.
    Kanevsky I; Surendran N; McElwee K; Lei L; Watson W; Pride M; Scully I; Karauzum H; Anderson A; Young M
    Vaccine; 2023 Oct; 41(45):6625-6629. PubMed ID: 37793976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn's disease - one year follow up.
    Kantsø B; Halkjær SI; Østergaard Thomsen O; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
    Infect Dis (Lond); 2019 Sep; 51(9):651-658. PubMed ID: 31290715
    [No Abstract]   [Full Text] [Related]  

  • 14. A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV.
    Wilck M; Barnabas S; Chokephaibulkit K; Violari A; Kosalaraksa P; Yesypenko S; Chukhalova I; Dagan R; Richmond P; Mikviman E; Morgan L; Feemster K; Lupinacci R; Chiarappa J; Madhi SA; Bickham K; Musey L;
    AIDS; 2023 Jul; 37(8):1227-1237. PubMed ID: 36939067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional immune responses to twelve serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults.
    Ahn JG; Kim HW; Choi HJ; Lee JH; Kim KH
    Vaccine; 2015 Sep; 33(38):4770-5. PubMed ID: 26277073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.
    Cooper D; Yu X; Sidhu M; Nahm MH; Fernsten P; Jansen KU
    Vaccine; 2011 Sep; 29(41):7207-11. PubMed ID: 21689707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV.
    Mohapi L; Pinedo Y; Osiyemi O; Supparatpinyo K; Ratanasuwan W; Molina JM; Dagan R; Tamms G; Sterling T; Zhang Y; Pedley A; Hartzel J; Kan Y; Hurtado K; Musey L; Simon JK; Buchwald UK;
    AIDS; 2022 Mar; 36(3):373-382. PubMed ID: 34750291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
    Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
    Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum IgM antibodies contribute to high levels of opsonophagocytic activities in toddlers immunized with a single dose of the 9-valent pneumococcal conjugate vaccine.
    Simell B; Nurkka A; Ekström N; Givon-Lavi N; Käyhty H; Dagan R
    Clin Vaccine Immunol; 2012 Oct; 19(10):1618-23. PubMed ID: 22875604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.